Anti-obesity drugs: status quo and recent advances / 中国医学科学院学报
Acta Academiae Medicinae Sinicae
;
(6): 243-247, 2011.
Article
Dans Anglais
| WPRIM
| ID: wpr-341422
ABSTRACT
Obesity has become a major health problem worldwide. The prevalence and morbidity of obesity-related diseases including diabetes, hypertension, cerebro-cardiovascular diseases, and tumors also have remarkably increased. Treatment of obesity poses a challenge for clinicians. Anti-obesity treatment is helpful to improve and even reverse obesity-related complications. Diet control and physical exercises remain the predominant interventions for obese patients. Anti-obesity drugs can be considered in those who respond poorly to behavioral intervention or those who have developed obesity-related complications. The commonly used anti-obesity drugs include gastrointestinal lipase inhibitors and appetite suppressants. Glucagon-like peptide 1 has also been found to be effective in reducing body weight. Some more drugs are under development, which include selective 5-HT 2c agonist, β3 receptor agonist, and melanocortin receptor 4 agonist, may also be promising.
Texte intégral:
Disponible
Indice:
WPRIM (Pacifique occidental)
Sujet Principal:
Anorexigènes
/
Agents antiobésité
/
Utilisations thérapeutiques
/
Traitement médicamenteux
/
Glucagon-like peptide 1
/
Obésité
Limites du sujet:
Humains
langue:
Anglais
Texte intégral:
Acta Academiae Medicinae Sinicae
Année:
2011
Type:
Article
Documents relatifs à ce sujet
MEDLINE
...
LILACS
LIS